Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 6/20 | 0.51 |
| ▸ | TGFBR1 | P36897 | 3/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | PKM | P14618 | 1/20 | 0.48 |
| ▸ | BCHE | P06276 | 1/20 | 0.46 |
| ▸ | SFRP1 | Q8N474 | 1/20 | 0.46 |
| ▸ | STS | P08842 | 1/20 | 0.46 |
| ▸ | GPR119 | Q8TDV5 | 5/20 | 0.46 |
| ▸ | LIMK2 | P53671 | 1/20 | 0.45 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.44 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.44 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.44 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1991648 | 0.77 | L3MBTL1 (0.62) | HTR6KDM4EPKMGPR119CHRM2 | |
| Hydrochloric Acid SCHEMBL4068380 | 0.76 | HTR6 (0.63) | HTR6 | |
| SCHEMBL4777921 | 0.76 | KDM4E (0.54) | HTR6KDM4EPKMSTSGPR119 | |
| SCHEMBL31668261 | 0.75 | HTR6 (0.47) | HTR6KDM4EPKMBCHEGPR119 | |
| SCHEMBL4686828 | 0.74 | KDM4E (0.58) | TGFBR1KDM4EPKMSTSGPR119 | |
| SCHEMBL8444728 | 0.74 | KDM4E (0.58) | HTR6TGFBR1KDM4EPKMSTS | |
| SCHEMBL16880224 | 0.74 | HTR6 (0.46) | HTR6KDM4EPKMBCHESTS | |
| SCHEMBL5705187 | 0.74 | HTR6 (0.60) | HTR6TGFBR1BCHEGPR119 | |
| SCHEMBL26116198 | 0.73 | HTR6 (0.48) | HTR6TGFBR1KDM4EPKMBCHE | |
| SCHEMBL4768843 | 0.73 | KDM4E (0.51) | HTR6KDM4EPKMGPR119CHRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7589108-B2 | 1-Heterocyclylalkyl-3-sulfonylindole or -indazole derivatives as 5-hydroxytryptamine-6 ligands | WYETH (US) | 2009-09-15 | — | — | US | disclosed |
| US-20060030593-A1 | 1-Heterocyclylalkyl-3-sulfonylindole or -indazole derivatives as 5-hydroxytryptamine-6 ligands | WYETH (US) | 2006-02-09 | — | — | US | disclosed |
| US-6995176-B2 | 1-heterocyclylalkyl-3-sulfonyl-indole or -indazole derivatives as 5-hydroxytryptamine-6 ligands | WYETH (US) | 2006-02-07 | — | — | US | disclosed |
| EP-1554244-A1 | 1-HETEROCYCLYLALKYL-3-SULFONYLINDOLE OR -INDAZOLE DERIVATIVES AS 5-HYDROXYTRYPTAMINE-6 LIGANDS | Wyeth (US) | 2005-07-20 | — | — | EP | disclosed |
| US-20040024023-A1 | 1-Heterocyclylalkyl-3-sulfonyl-indole or -indazole derivatives as 5-hydroxytryptamine-6 ligands | WYETH | 2004-02-05 | — | — | US | disclosed |
| WO-2004009548-A1 | 1-HETEROCYCLYLALKYL-3-SULFONYLINDOLE OR -INDAZOLE DERIVATIVES AS 5-HYDROXYTRYPTAMINE-6 LIGANDS | WYETH (US) | 2004-01-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060030593-A1 | 1-Heterocyclylalkyl-3-sulfonylindole or -indazole derivatives as 5-hydroxytryptamine-6 ligands | HTR6, HTR3A, HTR5A | HTR6 1/4885TGFBR1 2275/4885KDM4E 4343/4885 |
| US-20040024023-A1 | 1-Heterocyclylalkyl-3-sulfonyl-indole or -indazole derivatives as 5-hydroxytryptamine-6 ligands | HTR6, HTR3A, HTR1A | HTR6 1/4885TGFBR1 2059/4885KDM4E 4067/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.